Effects of melatonin supplementation in the treatment of fibrocystic changes of breast
Phase 3
Recruiting
- Conditions
- Breast fibrocystic disease.Benign mammary dysplasia
- Registration Number
- IRCT20170513033941N68
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Patients aged 18-45 years
women diagnosed with fibrocystic breast disease
having moderate or severe cyclic mastalgia
BMI = 25
Exclusion Criteria
Malignant breast diseases
Taking medicines for reducing pain (such as danazol, tamoxifen, bromocriptine) over the past three months
Menopause women
Pregnant or breastfeeding women
Psychological diseases
Unwillingness to cooperate
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.
- Secondary Outcome Measures
Name Time Method